Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Product update

Contraindications for Eviplera

Additions have been made to the list of mutations that exclude patients with HIV from treatment with Eviplera (emtricitabine/rilpivirine/tenofovir; Gilead). These are the tenofovir resistance-associated substitution K70E, and the combination of L100I+K103N as a rilpivirine resistance-associated substitution.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066076

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.